APR 07, 2016 7:30 AM PDT

The Personalis ACE CancerPlus Test: A Comprehensive DNA & RNA Sequencing Solution for Guiding Clinical Care & Improving Patient Outcomes

Speaker
  • Field Applications Scientist, Personalis
    Biography
      Heather Wetzel is a Field Applications Scientist and Genetic Counselor at Personalis, Inc. She received her Masters in Genetic Counseling from Northwestern University in 2006 and board certification in genetic counseling in 2007. Prior to working at Personalis, Heather worked for 8 years as a clinical Genetic Counselor in specialties including pediatrics, cancer, and prenatal at the University of Illinois, Northwestern, Stanford, and the University of California - San Francisco. Heather currently supports the clinical products at Personalis including the ACE Clinical Exome for Mendelian Diagnostics and the newly launched ACE CancerPlus Test for tumor profiling.

    Abstract

    Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and interpretation company, has developed a tumor-profiling test that provides clinicians with accurate and comprehensive analysis and clinical reporting of 181 genes to guide treatment decisions.

    Learning Objectives
     

    1. Understand the current industry challenges with regard to NGS technology and tumor profiling for clinical care.
    2. Appreciate how the use of Personalis’ accuracy and content enhanced (ACE) sequencing platform with DNA & RNA analysis improves precision and reporting in solid tumor testing.
    3. Recognize, through case studies, some of the more common molecular changes identified that may assist in therapeutic management.

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    Loading Comments...
    Show Resources
    Attendees
    • See more